TY - JOUR
T1 - Bioinformatics Designing and Molecular Modelling of a Universal mRNA Vaccine for SARS-CoV-2 Infection
AU - Oladipo, Elijah Kolawole
AU - Adeniyi, Micheal Oluwafemi
AU - Ogunlowo, Mercy Temiloluwa
AU - Irewolede, Boluwatife Ayobami
AU - Adekanola, Victoria Oluwapelumi
AU - Oluseyi, Glory Samuel
AU - Omilola, Janet Abisola
AU - Udoh, Anietie Femi
AU - Olufemi, Seun Elijah
AU - Adediran, Daniel Adewole
AU - Olonade, Aanuoluwapo
AU - Idowu, Usman Abiodun
AU - Kolawole, Olatunji M
AU - Oloke, Julius Kola
AU - Onyeaka, Helen
PY - 2022/12/9
Y1 - 2022/12/9
N2 - At this present stage of COVID-19 re-emergence, designing an effective candidate vaccine for different variants of SARS-CoV-2 is a study worthy of consideration. This research used bioinformatics tools to design an mRNA vaccine that captures all the circulating variants and lineages of the virus in its construct. Sequences of these viruses were retrieved across the six continents and analyzed using different tools to screen for the preferable CD8+ T lymphocytes (CTL), CD4+ T lymphocytes (HTL), and B-cell epitopes. These epitopes were used to design the vaccine. In addition, several other co-translational residues were added to the construct of an mRNA vaccine whose molecular weight is 285.29686 kDa with an estimated pI of 9.2 and has no cross affinity with the human genome with an estimated over 68% to cover the world population. It is relatively stable, with minimal deformability in its interaction with the human innate immune receptor, which includes TLR 3 and TLR 9. The overall result has proven that the designed candidate vaccine is capable of modulating cell-mediated immune responses by activating the actions of CD4+ T cells, natural killer cells, and macrophages, and displayed an increased memory T cell and B cell activities, which may further be validated via in vivo and in vitro techniques.
AB - At this present stage of COVID-19 re-emergence, designing an effective candidate vaccine for different variants of SARS-CoV-2 is a study worthy of consideration. This research used bioinformatics tools to design an mRNA vaccine that captures all the circulating variants and lineages of the virus in its construct. Sequences of these viruses were retrieved across the six continents and analyzed using different tools to screen for the preferable CD8+ T lymphocytes (CTL), CD4+ T lymphocytes (HTL), and B-cell epitopes. These epitopes were used to design the vaccine. In addition, several other co-translational residues were added to the construct of an mRNA vaccine whose molecular weight is 285.29686 kDa with an estimated pI of 9.2 and has no cross affinity with the human genome with an estimated over 68% to cover the world population. It is relatively stable, with minimal deformability in its interaction with the human innate immune receptor, which includes TLR 3 and TLR 9. The overall result has proven that the designed candidate vaccine is capable of modulating cell-mediated immune responses by activating the actions of CD4+ T cells, natural killer cells, and macrophages, and displayed an increased memory T cell and B cell activities, which may further be validated via in vivo and in vitro techniques.
KW - SARS-CoV-2
KW - mRNA vaccine
KW - bioinformatics
KW - variants
KW - lineages
U2 - 10.3390/vaccines10122107
DO - 10.3390/vaccines10122107
M3 - Article
C2 - 36560516
SN - 2076-393X
VL - 10
JO - Vaccines
JF - Vaccines
IS - 12
M1 - 2107
ER -
